{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T05:14:14Z","timestamp":1773638054814,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,16]]},"DOI":"10.7759\/cureus.11504","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T13:49:21Z","timestamp":1605534561000},"source":"Crossref","is-referenced-by-count":9,"title":["Yescarta: A New Era for Non-Hodgkin Lymphoma Patients"],"prefix":"10.7759","author":[{"given":"Salma  M","family":"AlDallal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"SEER Cancer Statistics Review (CSR) 1975-2014. (2018). Accessed. September 9, 2020: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2014\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini L","year":"2016","unstructured":"Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016, 127:2072-2081. 10.1182\/blood-2015-11-624312","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624320","article-title":"The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma","volume":"127","author":"Kuruvilla J","year":"2016","unstructured":"Kuruvilla J. The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma. Blood. 2016, 127:2093-2100. 10.1182\/blood-2015-11-624320","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The Principles of Engineering Immune Cells to Treat Cancer","volume":"168","author":"Lim WA","year":"2017","unstructured":"Lim WA, June CH. The Principles of Engineering Immune Cells to Treat Cancer. Cell. 2017, 168:724-740. 10.1016\/j.cell.2017.01.016","journal-title":"Cell"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain M","year":"2017","unstructured":"Sadelain M, Rivi\u00e8re I, Riddell S. Therapeutic T cell engineering. Nature. 2017, 545:423-431.","journal-title":"Nature"},{"key":"ref6","article-title":"The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma","volume":"6","author":"Lulla PD","year":"2018","unstructured":"Lulla PD, Hill LC, Ramos CA, Heslop HE. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018, 6:375-386.","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.2147\/CMAR.S163225","article-title":"Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel","volume":"11","author":"Viardot A","year":"2019","unstructured":"Viardot A, Wais V, Sala E, Koerper S. Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel. Cancer Manag Res. 2019, 11:2393-2404.","journal-title":"Cancer Manag Res"},{"key":"ref8","unstructured":"Yescarta. (2017). Accessed. September 9, 2020: https:\/\/www.kitepharma.com\/news\/press-releases\/2020\/5\/yescarta-axicabtagene-ciloleucel-demonstrates-high-rates-of-res...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer JN","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, et al.. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015, 33:540-549. 10.1200\/JCO.2014.56.2025","journal-title":"J Clin Oncol"},{"key":"ref10","article-title":"Updated phase 1 results from ZUMA- 1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti- CD19 CAR T cells) in refractory aggressive B-cell non- Hodgkin lymphoma (NHL)","volume":"21","author":"Siddiqi T","year":"2016","unstructured":"Siddiqi T, Neelapu S, Locke F, et al.. Updated phase 1 results from ZUMA- 1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti- CD19 CAR T cells) in refractory aggressive B-cell non- Hodgkin lymphoma (NHL). Mol Ther. 2016, 21:791-2016.","journal-title":"Mol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1387905","article-title":"Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL","volume":"59","author":"Roberts ZJ","year":"2018","unstructured":"Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Leuk Lymphoma. 2018, 59:1785-1796. 10.1080\/10428194.2017.1387905","journal-title":"Leuk Lymphoma"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(16)33096-9","article-title":"Production of KTE-C19 (anti-CD19 CAR T cells) for ZUMA- 1: a phase 1\/2 multi-center study evaluating safety and efficacy in subjects with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"1016","author":"Better M","year":"2016","unstructured":"Better M, Chiruvolu V, Oliver J, et al.. Production of KTE-C19 (anti-CD19 CAR T cells) for ZUMA- 1: a phase 1\/2 multi-center study evaluating safety and efficacy in subjects with refractory aggressive non-Hodgkin lymphoma (NHL). Mol Ther. 2016, 1016:1525-0016. 10.1016\/S1525-0016(16)33096-9","journal-title":"Mol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al.. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017, 377:2531-2544. 10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"ref14","unstructured":"AACR 2017 | Primary results from the pivotal ZUMA-1 trial of KTE-C19 in refractory aggressive Non-Hodgkin Lymphoma patients. (2017). Accessed. September 9, 2020: https:\/\/lymphomahub.com\/medical-information\/aacr-2017-or-primary-results-from-the-pivotal-zuma-1-trial-of-kte-c19-in-...."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee DW","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al.. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014, 124:188-195. 10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude SL","year":"2014","unstructured":"Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014, 20:119-122. 10.1097\/PPO.0000000000000035","journal-title":"Cancer J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.4426.4426","article-title":"Cyclophosphamide and fludarabine conditioning chemotherapy induces a key homeostatic cytokine profile in patients prior to CAR T cell therapy","volume":"126","author":"Bot A","year":"2015","unstructured":"Bot A, Rossi J, Yizhou J, et al.. Cyclophosphamide and fludarabine conditioning chemotherapy induces a key homeostatic cytokine profile in patients prior to CAR T cell therapy. ASH Ann Meeting Abstracts. 2015, 126:4426. 10.1182\/blood.V126.23.4426.4426","journal-title":"ASH Ann Meeting Abstracts"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/36389-yescarta-a-new-era-for-non-hodgkin-lymphoma-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:19:59Z","timestamp":1707506399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/36389-yescarta-a-new-era-for-non-hodgkin-lymphoma-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.11504","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,16]]}}}